Mellon Family Investment Co V 4
4 · Trevi Therapeutics, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4Exit
Mellon Family Investment Co V
10% Owner
Transactions
- Conversion
Common Stock
[F1][F2]2019-05-09+222,816→ 222,816 total - Other
Common Stock
[F3][F2]2019-05-09+24,340→ 247,156 total - Purchase
Common Stock
[F2]2019-05-09$10.00/sh+100,000$1,000,000→ 347,156 total - Conversion
Series C Preferred Stock
[F1][F2]2019-05-09−1,908,450→ 0 total→ Common Stock (222,816 underlying)
Footnotes (3)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]MFIC V, LLC, the general partner of Mellon Family Investment Company V, has sole voting and investment control with respect to shares of the Issuer's Common Stock held by Mellon Family Investment Company V.
- [F3]Consists of shares transferred to Mellon Family Investment Company V by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering.